Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

472.200
-14.800-3.04%
Volume:349.28K
Turnover:164.29M
Market Cap:112.86B
PE:-285.00
High:500.000
Open:500.000
Low:459.000
Close:487.000
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:0.70
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.657
ROE:2.92%
ROA:-0.04%
PB:18.07
PE(LYR):-285.00
PS:46.24

Loading ...

Movement Alert|Kelun-Biotech Rises 3.62% at Open, Investment Banks Raise Target Prices Amid Institutional Accumulation Wave

Market Focus
·
Jul 22

Movement Alert|Kelun-Biotech Rises 3.08% in Regular Trading, Multiple Investment Banks Raise Target Prices Amid Institutional Buying Wave

Market Focus
·
Jul 21

JPMorgan Raises Price Target for SKB BIO to HK$648, Maintains Overweight Rating

Deep News
·
Jul 20

Movement Alert|Kelun-Biotech Rises 3.41% in Regular Trading, Multiple Banks Raise Target Price Amid Biotech Sector Rebound

Market Focus
·
Jul 20

Movement Alert|Kelun-Biotech Falls 3.25% in Regular Trading, Post-Clinical-Milestone Profit-Taking Continues Amid Sector-Wide Weakness

Market Focus
·
Jul 17

HBM Holdings's Asthma Drug Candidate Secures China's Approval

MT Newswires Live
·
Jul 16

Goldman Sachs Reiterates Buy Rating on Kelun-Bota Biopharma, Raises Target Price to HK$582.95

Deep News
·
Jul 16

Movement Alert|Kelun-Biotech Falls 3.45% in Regular Trading, Profit-Taking After Prior Session Clinical Data Rally

Market Focus
·
Jul 16

Merck Rises After Partner Kelun-biotech Reports Positive Keytruda Lung Cancer Study

Reuters
·
Jul 15

SKB BIO Secures HK$2.7 Billion Placement to Fund R&D, Total Post-IPO Fundraising Approaches HK$7 Billion

Deep News
·
Jul 15

China NMPA Clears Kelun-biotech, Harbour Biomed Asthma IND for Skb575/hbm7575

Reuters
·
Jul 15

Hbm Holdings - Hbm7575 Co-developed by Harbour Biomed and Kelun-biotech

THOMSON REUTERS
·
Jul 15

Kelun-biotech and Harbour Biomed Announce Nmpa Approval of Ind Application for Skb575/hbm7575 for the Treatment of Asthma

THOMSON REUTERS
·
Jul 15

Kelun-Biotech's Lung Cancer Drug Trial Meets Primary Endpoint

MT Newswires Live
·
Jul 15

Innovative Drug Stocks Surge Following Inclusion in National Essential Medicines List, Accelerating Grassroots Access

Stock News
·
Jul 15

Movement Alert|Kelun-Biotech Rises 10.8% in Regular Trading, Core TROP2 ADC Achieves Phase III Primary Endpoint in PD-L1 Negative NSCLC

Market Focus
·
Jul 15

Sichuan Kelun-biotech Biopharma Says Primary Endpoint Met for Phase 3 Study of Lung Cancer Treatment

Reuters
·
Jul 15

SKB BIO's Pivotal Drug Candidate Achieves Primary Endpoint in Phase 3 Lung Cancer Trial

Stock News
·
Jul 15

Kelun-Biotech’s sac-TMT + Keytruda Clears Phase 3 PFS Hurdle in First-Line PD-L1-Negative NSCLC

Bulletin Express
·
Jul 15

Kelun-biotech Says Phase 3 Sac-tmt Plus Keytruda Meets PFS Endpoint in First-line Pd-l1-negative NSCLC

Reuters
·
Jul 15